GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
Rating: AEGR
Outperform $111

Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR) reiterated to Outperform with price target $111 by FBR Capital

Thursday,  Oct 31, 2013  8:25 AM ET by Kristen Bailey

FBR Capital reiterated Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR) to Outperform with price
target $111. FBR Capital rated Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR) to Outperform with price target $105 on 10/30/2013, when the price was $95.45.

Aegerion Pharmaceuticals, Inc. (Aegerion) is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat severe lipid disorders. Its lead compound, lomitapide, is a microsomal triglyceride transfer protein inhibitor (MTP-I), which limits secretion of cholesterol and triglycerides from the intestines and the liver, the main sources of lipids in the body. The Company is initially developing lomitapide as an oral, once-a-day treatment for patients with a rare genetic lipid disorder called homozygous familial hypercholesterolemia (HoFH). HoFH is a genetic lipid disorder caused by defects in both copies of the low-density lipoprotein (LDL) receptor genes, resulting in impaired or total loss of function in the LDL receptor.

FBR Capital uses a highly disciplined analysis focused on intrinsic value, which we developed to critically examine the capital structure of the companies we cover, as well as their competitive positions and the growth opportunities within their industries. We apply this discipline – which helps us assess how effectively a company’s managers deploy the capital entrusted to them – not only in our published research but also when making investing and underwriting judgments.



RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy